(112 days)
Not Found
No
The device description and performance studies focus on the chemical and physical properties of a hydrogel wound dressing with antimicrobial silver, with no mention of AI or ML technologies.
Yes
The device is described as a wound dressing intended for healing various skin and wound conditions, which aligns with the definition of a therapeutic device.
No
The device is a wound care gel intended to maintain a moist wound environment and deliver antimicrobial silver, not to diagnose a condition.
No
The device description clearly states it is a hydrogel wound dressing supplied in tubes, indicating it is a physical product, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the management of wounds and skin conditions. This is a therapeutic application, not a diagnostic one.
- Device Description: The device is a wound dressing (hydrogel) with antimicrobial properties. It is applied externally to the wound.
- Lack of Diagnostic Function: There is no mention of the device being used to test samples (like blood, urine, or tissue) to diagnose a disease or condition.
- Performance Studies: The performance studies focus on the antimicrobial efficacy of the gel as a barrier, not on its ability to diagnose anything.
IVD devices are used to examine specimens derived from the human body to provide information for the diagnosis, prevention, monitoring, treatment, or alleviation of disease. This device does not fit that description.
N/A
Intended Use / Indications for Use
Silver Shield Antimicrobial Skin and Wound Gel is intended for OTC use for Abrasions and lacerations and under the supervision of a health care professional in the management of Stage 1-1V Pressure Ulcers, Partial and Full thickness Wounds, Diabetic Foot and Leg Ulcers, Grafted and donor sites.
Product codes (comma separated list FDA assigned to the subject device)
MGO, FRO
Device Description
Silver Shield Antimicrobial Skin and Wound Gel is a clear, amorphous hydrogel wound dressing that helps maintain a moist wound environment that is conducive to healing, by either absorbing the wound exudates or donating the moisture while delivering antimicrobial silver. The gel matrix of the Silver Shield™ Antimicrobial Skin and Wound Gel is composed of a silver complex and an inert viscosity-modifying agent that imparts viscous hydrogel properties. Silver Shield™ Antimicrobial Skin and Wound Gel will be supplied in collapsible blind ended, heatsealed, co-extruded tubes fitted with a "flip top" dispenser closure. This reusable tube will be placed in a chipboard dispenser box with a package insert.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
OTC use; under the supervision of a health care professional
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
USP preservative efficacy testing was performed to establish that Silver Shield Antimicrobial skin and Wound Gel is an effective antimicrobial barrier. The test was performed using the test organisms in accordance with USP and some additional bacterial strains such as antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), and Vancomycin resistant Enterococcus (VRE).
Various test models were used for determining the anti-micorbial barrier properties. All tests have met or exceeded the requirements as set forth in USP for preservative efficacy test as well as the testing performed for the predicate device K011994.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
N/A
0
| Company: | Anacapa™ Technologies, Inc.
301, E. Arrow Hwy, suite 106
San Dimas, CA 91773 | NOV 2 1 2006 |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------|--------------|
| Contact : | Ila Doshi , Official FDA Correspondent
Telephone: 909-394-7795
Fax: 909-394-9895
Email: ila@anacapatechnologies.net | |
| Date of Preparation: | Nov. 10, 2006 | |
| Device Name (proprietary): | Silver Shield™ Antimicrobial Skin and Wound Gel | |
| Common Name: | Moist Antimicrobial wound filler OR
Amorphous Hydrogel Wound Dressing | |
| Classification Name: | Dressing, wound and burn, hydrogel w/drug and/or biologic | |
| Classification: | Unclassified | |
| Product Code: | MGO | |
Legally Marketed Devices for substantial equivalence comparison:
Silver Shield Antimicrobial Skin and Wound Gel is substantially equivalent to AcryDerm Silver Antimicrobial Wound Gel, 510(K) # K011994. (AcryMed, Inc., OR also distributed under the trade name SilvaSorb™ Gel, Silver Antimicrobial Wound Gel (Medline Industries, Inc.)
Description of Device:
Silver Shield Antimicrobial Skin and Wound Gel is a clear, amorphous hydrogel wound dressing that helps maintain a moist wound environment that is conducive to healing, by either absorbing the wound exudates or donating the moisture while delivering antimicrobial silver. The gel matrix of the Silver Shield™ Antimicrobial Skin and Wound Gel is composed of a silver complex and an inert viscosity-modifying agent that imparts viscous hydrogel properties. Silver Shield™ Antimicrobial Skin and Wound Gel will be supplied in collapsible blind ended, heatsealed, co-extruded tubes fitted with a "flip top" dispenser closure. This reusable tube will be placed in a chipboard dispenser box with a package insert.
Intended Use of the Device:
Silver Shield Antimicrobial Skin and Wound gel is a clear, amorphous hydrogel wound dressing which functions as a long lasting antimicrobial barrier by inhibiting the growth of common bacteria such as: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Serratia marcescens, including antibiotic resistant strains: MRSA & VRE, as well as fungi such as Candida albicans and Aspergillus niger. Silver Shield™ Antimicrobial Skin and Wound Gel is intended for OTC use for Abrasions and lacerations and under the supervision of a health care professional in the management of Stage 1-1V Pressure Ulcers, Partial and Full thickness Wounds, Diabetic Foot and Leg Ulcers, Grafted and donor sites
1
Device: Silver Shield™ Antimicrobial Skin and Wound Gel K062212: Additional information Section D: 510(K) Summary continued Anacapa
Technologies, Inc
Device Technological Characteristics:
Silver Shield™ Antimicrobial Skin and Wound Gel exhibits the capacity to absorb moisture and control light wound exudate. Antimicrobial activity is embodied in the content of silver contained in Silver Shield™ Antimicrobial Skin and Wound Gel. The antimicrobial silver inhibits the growth of microorganisms and thus acts as a preservative that controls the microbial contamination of the product as well as acts as an antimicrobial barrier and thus prevents microbiological contamination of the application site that may help reduce infection. Hydrogel characteristics are imparted by an inert viscosity enhancing agent rather than "hydrophilic polyacrylate absorbent microspheres" contained in the predicate device (AcyrDerm Silver Antimicrobial wound Gel, Acrymed, Inc., OR; AKA Silvasorb™ Antimicrobial Wound Gel, 510(K) # K011994) . Silver Shield™ Antimicrobial Skin and Wound Gel represents substantial equivalence to the predicate device.
Manufacturing:
Silver Shield™ Antimicrobial skin and Wound Gel will be manufactured according to product specifications and under the guidelines of Good Manufacturing Practices (GMP). Risk analysis has been performed to identify possible failure mode during manufacturing. Manufacturing controls have been developed and implemented to address the identified risk factors based on the criticality of the failure mode. All established GMPs will assure that the device manufactured at Anacapa™ Technologies, Inc meets all the established specification prior to release and is safe and effective for its intended use.
Performance Testing:
USP preservative efficacy testing was performed to establish that Silver Shield Antimicrobial skin and Wound Gel is an effective antimicrobial barrier. The test was performed using the test organisms in accordance with USP and some additional bacterial strains such as antibiotic resistant Methicillin Resistant Staphylococcus aureus (MRSA), and Vancomycin resistant Enterococcus (VRE).
Various test models were used for determining the anti-micorbial barrier properties. All tests have met or exceeded the requirements as set forth in USP for preservative efficacy test as well as the testing performed for the predicate device K011994
Substantial Equivalence discussion:
The indications of use, technological properties, performance testing described above, for the Silver Shield Antimicorbial Skin and Wound Gel are substantially equivalent to those of predicate device AcyrDerm Silver Antimicrobial wound Gel, Acrymed, Inc., OR; AKA Silvasorb™ Antimicrobial Wound Gel, 510(K) # K011994. The performance testing exceeds the requirements as set forth by USP as well exceeds those demonstrated by the predicate device. The biocompatibility testing and the performance testing performed for the device also demonstrated that the device is safe and effective for the indications of use.
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Anacapa Technologies, Inc. % Ms. Ila Doshi 301 East Arrow Highway, Suite 106 San Dimas, California 91773
NOV 2 1 2006
Re: K062212
Trade/Device Name: Silver Shield™ Antimicrobial Skin Wound gel Regulatory Class: Unclassified Product Code: FRO Dated: October 16, 2006 Received: October 18, 2006
Dear Ms. Doshi:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally
3
Page 2 -- Ms. Ila Doshi
marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.
Sincerely yours,
Mark A. Millherson
Mark N. Melkerson Director Division of General, Restorative ' and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Device Name: Silver Shield™ Antimicrobial Skin Wound gel
Indications for use:
Silver Shield™ Antimicrobial Skin and Wound Gel is intended for OTC use for Abrasions and lacerations and under the supervision of a health care professional in the management of Stage 1-1 V Pressure Ulcers, Partial and Full thickness Wounds, Diabetic Foot and Leg Ulcers, Grafted and donor sites,
Prescription Use 人 (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Martin A. Millikan
Division of General. Restorative. and Neurological Devices
510(k) Number K062212
Concurrence of CDRH, Office of Device Evaluation (ODE)